Part of the difficulty in comparing maraviroc and leronlimab is that many authors will repeat the incorrect information that leronlimab does not interfere with the natural functions of CCR5.

trding's article perpetuates this mistake:

" (leronlimab) Doesn't block natural activity of ccr5 including no hepatotoxicity causing many others to fail their trial safety metric."

The "LL doesnt interfere with CCR5 function" theme derives from the early days of leronlimab research on HIV. "Not interfereing with CCR5 natural function" was desired to get LL approved for HIV.

All of Patterson's work clearly demonstrates that leronlimab interferes with some aspects of LL natural function, and that is precisely why LL is developing so many indications.